Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Journal of hepatology - 1 Jun 2012

Lachenmayer Anja, Toffanin Sara, Cabellos Laia, Alsinet Clara, Hoshida Yujin, Villanueva Augusto, Minguez Beatriz, Tsai Hung-Wen, Ward Stephen C, Thung Swan, Friedman Scott L, Llovet Josep M

Abstract excerpt

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown. We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxamic Acids

Share to Inhibitor of Apoptosis Proteins

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Share to Survivin

Source

Open in PubMed Open full text

Identifiers

PMID: 22322234
DOI: 10.1016/j.jhep.2012.01.009
PMCID: PMC3355195

Genes

HDAC3
HDAC5
CDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.PMID 22322234Read ↗

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with ImmunotherapySemantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular CarcinomaSemantic proximity Read ↗

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetics effectsSemantic proximity Read ↗

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCCSemantic proximity Read ↗

Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinomaSemantic proximity Read ↗

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSemantic proximity Read ↗

Pharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responsesSemantic proximity Read ↗

Preclinical Assessment of Synergistic Efficacy of MELK and CDKs inhibitors in Adrenocortical CancerSemantic proximity Read ↗

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer CellsSemantic proximity Read ↗

Expression and Function Analysis of Mitotic Checkpoint Genes Identifies TTK as a Potential Therapeutic Target for Human Hepatocellular CarcinomaSemantic proximity Read ↗

Baicalein Attenuates Hepatocellular Carcinoma Cell Survival and Induces Apoptosis Through the miR‑3178/HDAC10 pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.